November 3, 2016
LeoPharma and Morphosys join forces to fight skin diseases
LEO Pharma and MorphoSys AG have entered into a strategic alliance for the discovery and development of therapeutic antibodies for the treatment…
Pharmaceuticals, Biotechnology and Life Sciences
LEO Pharma and MorphoSys AG have entered into a strategic alliance for the discovery and development of therapeutic antibodies for the treatment…
LEO Pharma has named Svend Andersen as incoming EVP, Head of Region EUROPE+, who will assume the position of Executive Vice President, Head of Region EUROPE+, on January 1, 2016. He will join LEO Pharma’s Executive Leadership Team and report directly to the CEO.
LEO Pharma and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.